CTRI/2023/06/054259已完成1 期
A double-blind, randomised, single dose, single-centre, parallel group, two arm, comparative pharmacokinetic study of 420 mg intravenous solution for infusion of a Pertuzumab biosimilar candidate (AQ11) versus reference medicinal product (Perjeta®) in healthy, adult, male human subjects under fasting condition. - NA
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Healthy male human subjects, age in the range of 18 – 45 years both inclusive
- •2 Body Mass Index between 18.5-30 Kg / m2 extremes included and Body weight is at least 50 kg
- •3 Subjects with normal findings as determined by baseline history, physical examination and vital sign examination (blood pressure, pulse rate, respiration rate and body temperature).
- •4 Subjects with clinically acceptable findings as determined by haemogram, biochemistry, urinalysis, 12 lead ECG and chest X-ray (if done).
- •5 Willingness to follow the protocol requirements especially abstaining from xanthine containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit juice, any alcoholic products, the use of cigarettes and the use of tobacco products for 48.00 hours prior to dosing until after the last blood sample collection in the study and adherence to food, fluid and posture restrictions.
- •6 Subjects willing to sign Informed Consent Form.
- •7 Subjects with Left ventricular ejection fraction (LVEF) = 55 %.
- •8 Ability to comply with study and follow-up procedures.
- •9 Subjects who have no evidence of underlying disease during screening medical history.
- •10 No history of significant alcoholism.
- •11 No history of drug abuse (benzodiazepines and barbiturates) for the last one month and other illegal drugs (Appendix B) for the last 06 months.
- •12 Non-smokers, ex-smokers and moderate smokers will be included. Moderate smokers are defined as someone smoking 10 cigarettes or less per day, ex-smokers are someone who completely stopped smoking for at least 3 months. ?
排除标准
- •1 Known history of hypersensitivity to Pertuzumab or any of the excipients and/or related drugs.
- •2 Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
- •3 Subjects who have taken prescription medications or over-the-counter products (excluding vitamins, mineral supplements, and dietary supplements) within 28 days prior to administration of IMP.
- •4 Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood–forming organs, use of monoclonal antibody etc.
- •5 History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric diseases.
- •6 Participation in a clinical drug study or bioequivalence study 90 days prior to dosing of the present study.
- •7 History of malignancy or other serious diseases.
- •8 Blood donation 90 days prior to dosing of the present study.
- •9 Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.
- •10 Subjects with any other medical or psychiatric condition that could compromise study participation.
- •11 Found positive in breath alcohol test.
- •12 Found positive in urine test for drug abuse.
- •13 Any contraindication to blood sampling.
- •14 Male subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom etc.) are acceptable.
- •15 Major surgery or trauma within past one year of screening or anticipated need for any surgery during the study.
- •16 Any other condition or circumstance that, in the judgment of the Investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study
研究者
相似试验
已完成
不适用
A two-part, single dose, randomized, single-blinded, placebo controlled, phase I study to assess the safety and pharmacokinetics of oral MT1980 in healthy volunteers when dosed in the fasted stateNL-OMON51342Monument Therapeutics Limited26
尚未招募
不适用
A comparative pharmacokinetic study of AryoGen Pharmedâ??s AryoTrust (Trastuzumab) and â??HERCEPTINâ?? (Trastuzumab) in healthy, adult, male subjectsCTRI/2019/03/018218AryoGen Pharmed
尚未招募
1 期
Pharmacokinetic study of ZRC-3113 (Zydus Bevacizumab) and â??Avastinâ?¢â?? (Bevacizumab) in Healthy, Adult, Male subjectsCTRI/2020/01/022946Cadila Healthcare Ltd
已完成
不适用
A study comparing the blood levels of two trastuzumab formulations given as a single dose in healthy adult males.breast cancerACTRN12616000084482Dr Reddy's laboratories (Australia) Pty Ltd32
已完成
1 期
comparative pharmacokinetic study of Zydus Adalimumab (ZRC-3197) Injection and HUMIRA® Adalimumab Injection in healthy adult human subjects.CTRI/2019/01/017346Cadila Healthcare Ltd154